



Risk Factors for Mortality Among Patients on Hemodialysis in India: A Case-Control Study

Abstract

Background: Mortality in hemodialysis (HD) exceeds that of many solid organ cancers, despite advancements in care. This study was conducted to understand mortality in a large dialysis network of Indian HD patients and attempt to elucidate risk factors for mortality. **Materials and Methods:** We performed a case-control study of deaths among patients undergoing HD across 203 centers in India from January 1 to March 31, 2021 with an age-matched control of survivors. We reviewed demographic, dialysis, clinical, and socioeconomic factors. **Results:** Out of 17,659 patients on dialysis, 554 cases (non-survivors) and 623 age-matched controls (survivors) patients were followed up. The mean age was 54.9 ± 13.8 years, 70.5% (391) of them were males. Gender, BMI, dialysis frequency, HD vintage time, history of diabetes, and heart failure were similar between non-survivors and survivors. Lower education level, payment under public insurance, dialysis facility under a public-private partnership, vascular access via catheter, hemoglobin <8 g/dL levels, serum albumin <3.5 g/dL were significantly higher, hospitalizations in 3 months prior to death were more frequent among non-survivors. **Conclusion:** Factors including Hb <8 g/dL, temporary catheter, serum albumin less <3.5 g/dL, lower educational status, and dialysis under public insurance are associated with poorer survival in our population. Our findings have implications for designing interventions needed to improve outcomes for evolving policy and public-payer systems.

Keywords: Chronic kidney disease, End-stage renal disease, Hemodialysis, Mortality, Risk factors

Introduction

Hemodialysis (HD) is the dominant form of renal replacement therapy (RRT) worldwide, with survival of 93% at 1 year and 79% at 5 years in the 45–64 years age group in the ANZDATA registry.¹ TheUSRDS 2020 annual data report showed that incident patients who commenced HD in 2013 had 1-year survival of 97.5% and 5-year survival of 88.5%.² Among middle-income countries, the Malaysian renal registry reported a 1-year survival of 88%, 3-year survival of 68%, and 5-year survival of 53%.³ Dialysis Outcomes Practice Patterns Study (DOPPS) data in developed countries demonstrate that mortality is three times higher in the initial 3 months compared to a later period.⁴ In India, approximately 9% to 13% of patients on HD die within 1 year.⁵ Predictors of mortality in HD patients include dialysis duration, comorbidity, socioeconomic, and education status even in developed

countries.^{6,7} In the Indian context, HD has grown with improving public insurance payments, resulting in improved access for patients with poor socioeconomic status as illustrated in a recent review that highlighted the challenges in dialysis delivery in India.⁶ Few single-center studies in India have reported survival on HD and have rarely looked into the risk factors responsible for mortality.⁸ Our study was undertaken to understand mortality in a large dialysis network of Indian HD patients and to elucidate risk factors for mortality.

Materials and Methods

We performed a case-control study among prevalent patients undergoing maintenance HD (MHD) in a single large dialysis network across India. In 203 centers for HD, spread across 22 states, 17,659 (sampling frame) patients were registered from January 1 to March 31, 2021.

Suresh

Sankarasubaiyan¹,
Carol A. Pollock²,
Urmila Anandh³,
Savitha

Kasiviswanathan¹,
Kamal D. Shah¹

¹NephroPlus Dialysis Centers,
Hyderabad, Telangana, India,

²Department of Medicine,
Northern Clinical School, Kolling
Institute of Medical Research,
The University of Sydney,
Australia, ³Department of
Nephrology, Amrita Hospitals,
Faridabad, Delhi, India

Corresponding author:

Suresh Sankarasubaiyan,
NephroPlus Dialysis Centers,
Hyderabad, Telangana, India.
Email: suresh150902@gmail.
com

DOI: 10.25259/ijn_563_23



Received: 15-01-2024
Accepted: 31-05-2024
Online First: 08-08-2024
Published: 10-04-2025

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, transform, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

How to cite this article: Sankarasubaiyan S, Pollock CA, Anandh U, Kasiviswanathan S, Shah KD. Risk Factors for Mortality Among Patients on Hemodialysis in India: A Case-Control Study. Indian J Nephrol. 2025;35:390-6. doi: 10.25259/ijn_563_23

Selection of cases

All patients on MHD who expired from non-covid etiology from January to March 2021.

Criteria for selecting controls

Patients on maintenance hemodialysis (MHD) who survived during the same period from the same sampling frame by simple random sampling method. A total of 797 cases (non-survivors) and 797 controls (survivors) were selected in 1:1 basis. To avoid confounding factors, we considered age group or age frequency factor and the control subjects were categorized into age groups: 18–40 years, 41–60 years, and those over 60 years old. We excluded patients who were on HD for less than 90 days to avoid transition factors. We also excluded patients who were less than 18 years of age and arrived at the final number of 554 cases and 623 controls which still satisfies the 1:1 ratio (1:1.12) [Figure 1]. There were only nine COVID deaths during the study period. All deaths amongst cases during the study period were compared against age-stratified matched surviving HD patients (controls) for the following factors: demographic, dialysis, clinical, and socioeconomic factors. The demographic parameters included age, gender, educational qualification, and type of payer for dialysis: categorized as public insurance, out-of-pocket payment, and private insurance. The facility type was categorized as a public-private partnership or as private ownership. Dialysis factors included HD vintage, frequency of HD sessions per week as per the number of sessions done, type of vascular access and dialysis adequacy, hemoglobin

level, use of erythropoietin stimulating agent, and serum albumin. We could not measure the urine output of patients on dialysis. The cause of chronic kidney disease (categorized as diabetic and non-diabetic), co-morbidities: hypertension, history of heart failure, and hospitalization in the previous 3 months were recorded. Data were collected retrospectively from hospital management information systems and electronic medical records. The ethics committee approval was waived for this study by the Institutional Ethics Committee of Nephrocare since we have used deidentified data of patients who voluntarily consented to use their information for clinical research at the time of registration at NephroPlus, even before data was collected.

Statistical analysis

All cases and controls were selected by stratification into 18–40 years, 41–60 years, and more than 60 years [Table 1]. All continuous variables are reported as mean and ± standard deviation (SD), remaining variables in number (n) and proportions (%). The differences between groups were tested using an independent sample t-test. An initial Chi-square test was applied to compare all variables (risk factors) between survivors and non-survivors. The univariate and multivariate logistic regression was performed to calculate the risk of mortality in odds ratio with a 95% confidence interval. All variables were tested for univariate analysis and significant variables with p-value < 0.05 were tested for multivariate analysis. To analyze the data SPSS (IBM SPSS Statistics for Windows, Version 26.0, Armonk, NY: IBM Corp. Released 2019) was used. The significance level was fixed at 5% ($\alpha = 0.05$).

Results

Among patients dialyzed across 203 centers, 554 patients who died from non-COVID etiologies were included as cases and 623 survivors as controls during the study period.

The comparison of demographic, dialysis, clinical, and socioeconomic characteristics between non-survivors and survivors is shown in Table 2. Non-survivors were more likely to be illiterate (56.1% vs. 43.9%, $p < 0.01$). Age, gender, and BMI were not significantly different between the groups. Non-survivors had a higher proportion of central venous catheters during the 3 months study period (55.8% vs. 44.2%, $p < 0.05$), and lower hemoglobin




Figure 1: Methodology for selection of cases and controls for the study. HD: Hemodialysis.

Table 1: Age-matching in the study

	Group count		Total
	Cases	Controls	
Age (years)			
18 to 40	76	89	165
41 to 60	274	307	581
>60	204	227	431
Total	554	623	1177

Table 2: Comparison of demographic, dialysis, clinical, and socioeconomic factors between non-survivors and survivors on hemodialysis*

Characteristics	Non-survivors (n = 554) n (%)	Survivors (n = 623) n (%)	p-value
Demographic factors			
Age group (years)	55.57 ± 13.4	54.77 ± 13.1	0.303
Gender			0.688
Male	391 (47.5)	433 (52.5)	
Female	163 (46.2)	190 (53.8)	
Education			<0.001
Illiterate	197 (56.1)	154 (43.9)	
High school	171 (49.9)	172 (50.1)	
Higher secondary	89 (43.4)	116 (56.6)	
College	97 (34.9)	181 (65.1)	
BMI (Indian)	22.35 ± 4.7	22.88 ± 4.6	0.050
Dialysis factors			
HD duration (months)	21.76 ± 16.1	24.72 ± 18.1	0.003
HD frequency per week			
1X	14 (60.9)	9 (39.1)	0.281
2X	282 (45.5)	338 (54.5)	
3X	254 (48.7)	268 (51.3)	
Irregular/SOS	4 (33.3)	8 (66.7)	
Vascular access			0.011
AVF/AVG	453 (45.5)	543 (54.5)	
Catheter	101 (55.8)	80 (44.2)	
Dialysis adequacy	1.25 ± 0.1	1.26 ± 0.1	0.336
Clinical factors			
Hemoglobin level g/dL	8.77 ± 1.5	9.33 ± 1.5	0.000
Serum albumin g/dL	3.44 ± 0.6	3.62 ± 0.4	0.000
EPO use			0.139
Yes	536 (47.5)	592 (52.5)	
No	18 (36.7)	31 (63.3)	
Cause of CKD			0.042
Non-diabetic	343 (44.9)	421 (55.1)	
Diabetic	211 (51.1)	202 (48.9)	
Hypertension			
Systolic BP in mmHg	153.42 ± 26.3	149.98 ± 20.4	0.012
Diastolic BP in mmHg	83.13 ± 12.2	82.78 ± 11.1	0.614
History of heart failure			<0.039
Yes	45 (58.4)	32 (41.6)	
No	509 (46.3)	591 (53.7)	
Hospitalization in previous 3 months			<0.001
Yes	202 (74)	71 (26)	
No	352 (38.9)	552 (61.1)	
Socioeconomic factors			
Payer type			<0.001
Out of pocket	150 (43.5)	195 (56.5)	
Private insurance	118 (32.7)	243 (67.3)	
Public insurance	273 (59.6)	185 (40.4)	
Mixed	13 (100)	0	
Type of center			<0.001
Public-private	283 (56.7)	216 (43.3)	
Private hospital-based	271 (40)	407 (60)	

*Continuous variables reported as mean ± standard deviation. P>0.05 is considered as statistically significant. The values highlighted in bold are statistically significant. BMI: Body mass index, HD: Hemodialysis, SOS: When needed, AVF: Arteriovenous fistula, AVG: Arteriovenous graft, EPO: Erythropoietin, BP: Blood pressure, CKD: Chronic kidney disease

(mean 8.77 SD \pm 1.5, $p < 0.001$) and lower serum albumin (albumin < 3.5 g%, mean 3.44 SD \pm 0.6, $p < 0.001$) than survivors. The distribution of HD frequency and vintage time on HD was similar between the groups. Non-survivors were more likely to be paid by public insurance (59.6% vs. 40.4%, $p < 0.001$) and dialyzed in centers under public-private partnership (56.7% vs. 43.3%, $p < 0.001$), more likely to have diabetes (51.1% vs. 48.9%, $p < 0.05$) with prior history of heart failure (58.4% vs. 41.6%, $p < 0.05$) and prior hospitalization (74% vs. 26%, $p < 0.001$).

On multiple logistic regression shown in Table 3, illiteracy had an AOR of 2.68 (1.61, 4.48) $p < 0.001$ and high school education AOR 1.85 (1.21, 2.85), $p < 0.05$ for risk

of mortality compared to the college group. Patients under public insurance had an AOR: 1.93 (1.08, 3.46), $p < 0.05$ and patients dialyzed under a public-private partnership had an AOR 2.32 (1.38, 3.92), $p < 0.05$ for mortality compared to those with out-of-pocket payment. Among dialysis factors, the presence of temporary vascular access had AOR 1.53 (0.99, 2.39), $p < 0.05$, hemoglobin less than 8 g% had AOR 1.85 (1.13, 3.04) $p < 0.05$, and serum albumin less than 3.5 g/dL had AOR 1.98 (1.42, 2.77), $p < 0.05$. There was no difference in dialysis duration between groups. Hospitalization within the previous 3 months had AOR 0.18 (0.12, 0.27), $p < 0.001$. Though the comparison of proportions between cases and controls for factors such as the cause of CKD – diabetes and history of heart failure were significant,

Table 3: Univariate and multivariate logistic regression for mortality of patients on hemodialysis

Characteristics	OR (95% CI)	p-value	AOR (95% CI)	p-value
Demographic factors				
Age (years)				
18–40	Ref			
41–60	1.045 (0.739, 1.478)	0.803		
>60	1.052 (0.734, 1.508)	0.781		
Gender				
Female	Ref			
Male	1.053 (0.820, 1.351)	0.688		
Education status				
College	Ref			
Illiterate	2.387 (1.726, 3.302)	<0.001	2.689 (1.613, 4.483)	0.000
High school	1.855 (1.340, 2.568)	<0.001	1.859 (1.212, 2.851)	0.005
Higher Secondary	1.432 (.989, 2.073)	0.058	1.450 (0.909, 2.313)	0.118
BMI				
Obese (≥ 25.0)	Ref			
Underweight (< 18.5)	1.264 (0.883, 1.809)	0.201		
Normal (18.5–22.9)	1.109 (0.825, 1.490)	0.494		
Overweight (23– 24.9)	1.081 (0.752, 1.552)	0.674		
Dialysis factors				
HD duration (months)				
>36	Ref			
4–12	1.421 (1.037, 1.948)	0.029	1.338 (0.850, 2.105)	0.208
13–24	1.131 (0.817, 1.566)	0.458	1.224 (0.769, 1.948)	0.395
25–36	1.057 (0.719, 1.553)	0.779	1.221 (0.708, 2.106)	0.473
HD frequency per week				
2X	Ref			
1X	1.864 (0.795, 4.372)	0.152		
3X	1.136 (0.900, 1.435)	0.284		
Irregular/SOS	0.599 (0.179, 2.011)	0.407		
Vascular access				
AVF/AVG	Ref			
Catheter	1.513 (1.100, 2.081)	0.011	1.539 (0.990, 2.392)	0.045
Dialysis adequacy				
≥ 1.2	Ref			
< 1.2	1.513 (0.969, 2.361)	0.068		

(Continued)

Table 3: Continued.

Characteristics	OR (95% CI)	p-value	AOR (95% CI)	p-value
Clinical factors				
Hb level (g/dL)				
10–12	Ref			
>12	1.003 (0.474, 2.124)	0.993	1.187 (0.808, 1.745)	0.383
8–9.9	1.470 (1.113, 1.941)	0.007	1.224 (0.451, 3.323)	0.691
<8	2.697 (1.915, 3.798)	<0.001	1.859 (1.137, 3.041)	0.014
Serum albumin (g/dL)				
≥3.5	Ref			
<3.5	2.569 (1.940, 3.401)	<0.001	1.986 (1.424, 2.770)	0.000
EPO use				
Yes	Ref			
No	0.641 (0.355, 1.160)	0.142		
Cause of CKD				
Non-diabetic	Ref			
Diabetic	1.282 (1.009, 1.630)	0.042	1.362 (0.972, 1.911)	0.073
HTN				
No	Ref			
Yes	0.922 (0.698, 1.218)	0.568		
History of heart failure				
No	Ref			
Yes	0.612 (0.383, 0.978)	0.040	0.620 (0.325, 1.185)	0.148
Hospitalization in previous 3 months				
No	Ref			
Yes	0.224 (0.166, 0.303)	<0.001	0.189 (0.129, 0.277)	0.000
Socioeconomic factors				
Payer type				
Out of pocket	Ref			
Private insurance	0.631 (0.465, 0.857)	0.003	0.643 (0.440, 0.941)	0.063
Public insurance	1.918 (1.445, 2.546)	<0.001	1.936 (1.083, 3.461)	0.026
Mixed	21.706	0.998	16.65	0.998
Type of center				
Private hospital	Ref			
Public-private	1.968 (1.556, 2.488)	<0.001	2.327 (1.381, 3.920)	0.002

OR: Odds ratio, CI: Confidence interval, AOR: Adjusted odds ratio, BMI: Body mass index, HD: Hemodialysis, SOS: When needed, AVF: Arteriovenous fistula, AVG: Arteriovenous graft, Hb: Hemoglobin, EPO: Erythropoietin, CKD: Chronic kidney disease, HTN: Hypertension. P value < 0.05 is considered as statistically significant.

they were not significant on multiple logistic regression as mortality predictors.

Discussion

This study documents the important factor associated with the mortality on HD in India. Globally, race, temporary vascular access, dialysis adequacy, interdialytic interval, dialysis vintage time, nutritional status, diabetes, facility-doctor-patient ratio, and socioeconomic factors are known to influence survival on dialysis.^{9,10}

The increased mortality risk of central venous catheter use is consistent with previous large observational studies of the dialysis population. Among 5507 prevalent dialysis patients, arteriovenous graft (AVG) had a relative

risk (RR) of 1.41 ($p < 0.05$) and catheter had an RR of 1.54 ($p < 0.05$) for all-cause mortality, infection-related, and cardiac mortality among patients with and without diabetes similarly.¹¹ Among incident dialysis patients in the CHOICE study, the adjusted hazard ratio for mortality was 1.5 among patients using dialysis catheters compared to arteriovenous fistula (AVF).¹² We did not study specific catheter complications, including infection, catheter malfunction, and hospitalizations.

The impact of anemia on survival in HD patients was demonstrated in a DOPPS study where case-mix adjusted mortality risk and hospitalization decreased incrementally by 5% and 6% respectively, for every gram of increase in hemoglobin.¹³ In our study, 47% of non-survivors had

hemoglobin between 8 and 9.9 g/dL, and 61.7% had hemoglobin less than 8 g/dL with an AOR: 1.85 (1.13, 3.04 2.95). It likely reflects a suboptimal dose of erythropoietin and iron due to “out-of-pocket” payment and the lack of bundled payments under public insurance. Previous studies among the Indian HD population showed a high prevalence of anemia.^{8,14,15} Significantly, in India, the general population has a high prevalence of anemia with 57% and 25% of women and men, respectively, in the age group of 15 to 49 years as reported in the recent National Family Health Survey.¹⁶

In an analysis of the HEMO study, 12 nutritional indicators, including low body mass index and lower serum albumin were associated with lower survival in less than 6 months adjusted for case mix, comorbidity, and type of dialyzer.¹⁷ Similarly, in the DOPPS study, variations of nutritional indicators, including serum creatinine, serum albumin, BMI, and normalized protein catabolic rate were independently associated with poorer survival. These factors were also demonstrated to have a multiplicative effect on survival.¹⁸ In our study, non-survivors were more likely to have serum albumin less than 3.5 g/dL and were associated with higher AOR 1.98 (1.42, 2.77) for death.

In our study population, 51%–54% were on twice weekly HD and 3% once weekly HD. Twice weekly HD preserves residual renal function and potentially improves AVF longevity and better quality of life against the risks of lesser solute clearance, weight control, and electrolyte imbalance.¹⁹ Twice weekly HD could potentially be used for the initial phase of HD in low-resource settings, it is practiced more by patient choice, economic compulsion, and payer preferences too.^{8,14,15} We did not document the patients’ residual renal function for twice weekly HD. The small sample size and other confounders could be a limiting factor in demonstrating the lack of influence of HD frequency on survival.

The impact of socioeconomic factors on survival on hemodialysis across racial groups has been illustrated by an analysis of USRDS data.^{20,21} In the USA, segregated neighborhoods among blacks and lower median income among whites showed increased mortality risk.²⁰ In our population, patients under public insurance form a large proportion, and this is reported to be the most rapidly growing segment of the dialysis population in India.²² An analysis of insurance claims data from one state in India shows a drop-out rate of 36% in the first 6 months and a median survival of 170 for females to 198 days for males.²³ Despite government subsidies, the out-of-pocket burden on families for expenditure on dialysis is considerable at 27,564 Indian rupees, constituting up to 80% of household expenditure.²⁴ The incremental steps are required to lessen the cost burden resulting from biochemical monitoring access interventions and ancillary medications.

Hospitalization within 3 months had a highly significant AOR on mortality. It is well known that hospitalizations lead to high healthcare costs and result from infection, fluid overload, and cardiac and psychosocial comorbidity.²⁵ A DOPPS study of five European countries showed that hospitalization was significantly associated with the recent start of HD particularly in the settings of diabetes, cardiac disease, peripheral vascular disease, recent gastrointestinal (GI) bleeding, and psychiatric disease.²⁶ The presence of an irreversible chronic illness coupled with economic hardships is often responsible for skipping medications and dialysis. Missing dialysis often increases hospitalization and mortality.²⁷ Missed treatments had a positive association with all-cause and cardiovascular mortality and hospitalization.²⁸ In our context, dialysis factors including anemia, temporary vascular access, and low serum albumin level, combined with socioeconomic factors reflected in educational status, dependence on public insurance and therefore hurdles to access acute care could be drivers of hospitalization.

Our study's strength lies in its unique insights from a large dialysis network, highlighting health system challenges—both medical and non-medical—during the development of end-stage renal disease programs in lower-middle-income countries. Interventions focused on improving anemia, access management, and nutrition combined with education and support for the socio-economically challenged and poorly educated are essential to improve outcomes.

The limitations of this study are its retrospective nature, absence of data regarding blood pressure control, fluid management, other comorbidities particularly infections, objective cardiac functional assessment, residual renal function, access complications, and reasons for hospitalizations. The lab data were assessed from physical records at any time during the 3 months of the study period owing to the widely spread network of dialysis centers, lack of digital data, and limited ability to collect all data retrospectively.

In India, since the government is funding treatment for kidney failure, this study provides a roadmap to improve outcomes for patients commencing RRT beyond the provision of dialysis.

Factors such as lower educational status, vascular access using temporary catheters, hemoglobin level less than 8 g/dL, serum albumin less than 3.5 g/dL, hospitalization in previous 3 months, and dialysis using public insurance are associated with poor survival in our population. Hence, pre-dialysis care, planning for dialysis treatments, and early detection interventions are important to improve dialysis outcomes and to limit high-cost RRT in all jurisdictions.

Acknowledgments: The data were collected from various NephroPlus Dialysis Centres across India.

Conflicts of interest: There are no conflicts of interest.

References

1. ANZDATA 44th Annual Report 2021 (Data to 2020) – ANZDATA. Available from: <https://www.anzdata.org.au/report/anzdata-44th-annual-report-2021-data-to-2020/> [Accessed 18 Sep 2023].
2. US Renal Data System 2020 Annual Data Report: Epidemiology of kidney disease in the United States. *Am J Kidney Dis* 2021;77:A7–A8.
3. National Renal Registry. Malaysian society of nephrology, Kuala Lumpur, 2016. Available from: <https://www.msn.org.my/nrr/mdtr2016.jsp> [Accessed 18 Sep 2023].
4. Robinson BM, Zhang J, Morgenstern H, Bradbury BD, Ng LJ, McCullough KP, *et al.* Worldwide, mortality risk is high soon after initiation of hemodialysis. *Kidney Int* 2014;85:158–65.
5. Ravi Kumar P, Vinayagmoorthy V, Dongre A, Deshmukh P. Survival and analysis of predictors of mortality in patients undergoing hemodialysis in a rural hospital in Puducherry, India: A retrospective cohort study. *Open Urol Nephrol J* 2023;16.
6. Rivara MB, Adams SV, Kuttykrishnan S, Kalantar-Zadeh K, Arah OA, Cheung AK, *et al.* Extended-hours hemodialysis is associated with lower mortality risk in patients with end-stage renal disease. *Kidney Int* 2016;90:1312–20.
7. McClellan WM, McClellan CB. Poverty and mortality in hemodialysis patients. *J Am Soc Nephrol* 2013;24:165–7.
8. Sankarasubbaiyan S, Rajkumar A, Tangalvadi TA, Dawood US, Kaur P. Challenges and limitations of maintenance hemodialysis in urban South India. *Hemodial Int* 2007;11:485–91.
9. Chan KE, Maddux FW, Tolckoff-Rubin N, Karumanchi SA, Thadhani R, Hakim RM. Early outcomes among those initiating chronic dialysis in the United States. *Clin J Am Soc Nephrol* 2011;6:2642–9.
10. Bradbury BD, Fissell RB, Albert JM, Anthony MS, Critchlow CW, Pisoni RL, *et al.* Predictors of early mortality among incident US hemodialysis patients in the dialysis outcomes and practice patterns study (DOPPS). *Clin J Am Soc Nephrol* 2007;2:89–99.
11. Dhingra RK, Young EW, Hulbert-Shearon TE, Leavey SF, Port FK. Type of vascular access and mortality in U.S. hemodialysis patients. *Kidney Int* 2001;60:1443–51.
12. Garg AX, Mamdani M, Juurlink DN, van Walraven C. Network of Eastern Ontario Medical Laboratories (NEO-MeL). Identifying individuals with a reduced GFR using ambulatory laboratory database surveillance. *J Am Soc Nephrol* 2005;16:1433–9.
13. Pisoni RL, Bragg-Gresham JL, Young EW, Akizawa T, Asano Y, Locatelli F, *et al.* Anemia management and outcomes from 12 countries in the dialysis outcomes and practice patterns study (DOPPS). *Am J Kidney Dis* 2004;44:94–111.
14. Swarnalatha G, Ram R, Prasad N, Dakshinamurthy KV. End-stage renal disease patients on hemodialysis: A study from a tertiary care center in a developing country: Hemodialysis in a developing country. *Hemodial Int* 2011;15:312–19.
15. Chandrashekar A, Ramakrishnan S, Rangarajan D. Survival analysis of patients on maintenance hemodialysis. *Indian J Nephrol* 2014;24:206–13.
16. NFHS 5 - 2019 to 21. Compendium of fact sheets. Ministry of Health and Family Welfare. Government of India. Available from: https://main.mohfw.gov.in/sites/default/files/NFHS-5_Phase-II_0.pdf [Accessed 18 Sep 2023].
17. Dwyer JT, Larive B, Leung J, Rocco MV, Greene T, Burrowes J, *et al.* Are nutritional status indicators associated with mortality in the hemodialysis (HEMO) Study? *Kidney Int* 2005;68:1766–76.
18. Lopes AA, Bragg-Gresham JL, Elder SJ, Ginsberg N, Goodkin DA, Pifer T, *et al.* Independent and joint associations of nutritional status indicators with mortality risk among chronic hemodialysis patients in the dialysis outcomes and practice patterns study (DOPPS). *J Ren Nutr* 2010;20:224–34.
19. Yan Y, Ramirez S, Anand S, Qian J, Zuo L. Twice-weekly hemodialysis in China: Can it be a better option for initiation or maintenance dialysis therapy? *Semin Dial* 2017;30:277–81.
20. Kimmel PL, Fwu CW, Eggers PW. Segregation, income disparities, and survival in hemodialysis patients. *J Am Soc Nephrol* 2013;24:293–301.
21. Johns TS, Estrella MM, Crews DC, Appel LJ, Anderson CA, Ephraim PL, *et al.* Neighborhood socioeconomic status, race, and mortality in young adult dialysis patients. *J Am Soc Nephrol* 2014;25:2649–57.
22. Available from: <https://nhsrcindia.org/> [Accessed 08 Jul 2024], P.M.N.D. National Health Systems Resource Centre. Nhsrcindia.org. [Accessed 17 July 2023].
23. Shaikh M, Woodward M, John O, Bassi A, Jan S, Sahay M, *et al.* Utilization, costs, and outcomes for patients receiving publicly funded hemodialysis in India. *Kidney Int* 2018;94:440–5.
24. Bradshaw C, Gracious N, Narayanan R, Narayanan S, Safeer M, Nair GM, *et al.* Paying for hemodialysis in Kerala, India: A description of household financial hardship in the context of medical subsidy. *Kidney Int Rep* 2019;4:390–8.
25. Golestaneh L. Decreasing hospitalizations in patients on hemodialysis: Time for a paradigm shift. *Semin Dial* 2018;31:278–88.
26. Rayner HC, Pisoni RL, Bommer J, Canaud B, Hecking E, Locatelli F, *et al.* Mortality and hospitalization in hemodialysis patients in five European countries: Results from the dialysis outcomes and practice patterns study (DOPPS). *Nephrol Dial Transplant* 2004;19:108–20.
27. Assimon MM, Nguyen T, Katsanos SL, Brunelli SM, Flythe JE. Identification of volume overload hospitalizations among hemodialysis patients using administrative claims: A validation study. *BMC Nephrol* 2016;17:173.
28. Al Salmi I, Larkina M, Wang M, Subramanian L, Morgenstern H, Jacobson SH, *et al.* Missed hemodialysis treatments: International variation, predictors, and outcomes in the dialysis outcomes and practice patterns study (DOPPS). *Am J Kidney Dis* 2018;72:634–43.